CytRx Co. (CYTR) Position Boosted by Vanguard Group Inc.

Vanguard Group Inc. lifted its holdings in shares of CytRx Co. (NASDAQ:CYTR) by 53.9% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,823,123 shares of the biotechnology company’s stock after acquiring an additional 1,689,874 shares during the quarter. Vanguard Group Inc. owned approximately 3.17% of CytRx worth $3,024,000 as of its most recent filing with the Securities & Exchange Commission.

Separately, LMR Partners LLP bought a new position in CytRx in the second quarter worth $235,000. Institutional investors own 44.97% of the company’s stock.

CytRx Co. (NASDAQ CYTR) opened at $1.94 on Wednesday. CytRx Co. has a twelve month low of $1.71 and a twelve month high of $6.00.

Separately, ValuEngine downgraded CytRx from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st.

ILLEGAL ACTIVITY WARNING: This piece was posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at

CytRx Company Profile

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy.

Want to see what other hedge funds are holding CYTR? Visit to get the latest 13F filings and insider trades for CytRx Co. (NASDAQ:CYTR).

Institutional Ownership by Quarter for CytRx (NASDAQ:CYTR)

What are top analysts saying about CytRx Co.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CytRx Co. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit